Ticker
ABMD

Price
381.02
Stock movement up
+- (%)
Company name
ABIOMED Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Medical Devices
Marktkapitalisatie
17.18B
Ent waarde
17.16B
Prijs/Verkoop
16.00
Prijs/Boek
11.16
Div opbrengst
-
Div groei
-
Jaren van groei
-
FCF-uitkering
-
Trailing P/E
64.40
Toekomstige P/E
60.77
PEG
-
EPS-groei
-
1 jaar rendement
8.18%
3 jaar rendement
30.28%
5 jaar rendement
14.86%
10 jaar rendement
39.53%
Laatst bijgewerkt: 2023-03-10

DIVIDENDEN

ABMD keert geen dividend uit

WAARDERING

Waarderingsverhoudingen

Loading...
Gegevens over waarderingsratio's
Trailing P/E64.40
Prijs tot OCF68.45
Prijs tot FCF112.19
Prijs tot EBITDA46.29
EV tot EBITDA46.22

Waardering (verkoop/boekwaarde)

Loading...
Waarderingsgegevens (verkoop/boekwaarde)
Prijs tot verkoop16.00
Prijs te boeken11.16
EV naar verkoop15.97

FINANCIËN

Per aandeel

Loading...
Gegevens per aandeel
Huidig aantal aandelen45.09M
WPA (TTM)5.84
FCF per aandeel (TTM)3.35

Resultatenrekening

Loading...
Gegevens van de resultatenrekening
Inkomsten (TTM)1.07B
Brutowinst (TTM)873.51M
Bedrijfsresultaat (TTM)253.61M
Netto inkomsten (TTM)266.76M
WPA (TTM)5.84
Winst per aandeel (1 jaar vooruit)6.27

Marges

Loading...
Margegegevens
Brutomarge (TTM)81.32%
Operationele marge (TTM)23.61%
Winstmarge (TTM)24.84%

Balans

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Balansgegevens
Cash182.34M
Netto vorderingen94.47M
Totaal vlottende activa1.06B
Goodwill72.96M
Immateriële activa50.13M
Materiële vaste activa0.00
Totaal activa1.70B
Crediteuren35.07M
Schuld op korte/lange termijn0.00
Totaal vlottende passiva134.06M
Totaal passiva156.76M
Eigen vermogen1.54B
Netto materiële activa1.43B

Kasstroom

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Kasstroomgegevens
Bedrijfskasstroom (TTM)250.98M
Investeringsuitgaven (TTM)33.76M
Vrije kasstroom (TTM)153.14M
Betaalde dividenden (TTM)0.00

Financieel rendement

Loading...
Maak een gratis account aan of log in om toegang te krijgen tot deze grafiek.
Gegevens over financieel rendement
Rendement op eigen vermogen17.32%
Rendement op activa15.72%
Rendement op geïnvesteerd kapitaal17.32%
Contant rendement op geïnvesteerd kapitaal9.95%

VOORRAADINFORMATIE

Voorraadgrafiek

Loading...
Koersgegevens
Open381.02
Dagelijks hoog381.02
Dagelijks laag381.02
Dagelijks volume0K
Hoogtepunt aller tijden449.75
1y analistenraming363.00
Beta1.40
WPA (TTM)5.84
Dividend per aandeel-
Ex-div datum-
Volgende inkomsten datum26 Apr 2023

Negatief potentieel

Loading...
Nadeel potentiële gegevens
ABMDS&P500
Huidige prijsdaling vanaf het hoogste punt ooit-15.28%-19.84%
Hoogste prijsdaling-94.31%-56.47%
Datum van hoogste daling9 Oct 20029 Mar 2009
Gemiddelde daling vanaf de top-47.58%-11.51%
Gemiddelde tijd tot nieuwe high46 days13 days
Max tijd tot nieuwe hoogte3756 days1805 days
BEDRIJFSGEGEVENS
ABMD (ABIOMED Inc) company logo
Marketcap
17.18B
Marketcap categorie
Large-cap
Beschrijving
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
Werknemers
2003
Investeerdersrelaties
-
SEC-dossiers
CEO
Michael R. Minogue
Land
USA
Stad
Danvers
Type voorraad
Common stock
CCC-status
-
Dividendfrequentie
-
EVENEMENTEN EN PRESENTATIES
EvenementenPresentaties
Loading...
HET BEDRIJF BEGRIJPEN
Loading...
BEDRIJFSNIEUWS
Alle nieuwsPersberichten
Johnson & Johnson Inc. closed its acquisition of Danvers medical device maker Abiomed Inc. on Thursday. The deal weighed in at $16.6 billion, making it easily one of the largest acquisitions of the ye...
22 december 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
22 december 2022
DANVERS, Mass., December 21, 2022--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump
21 december 2022
S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel Dynamics in the S&P MidCap ...
19 december 2022
In this article, we discuss the 10 best performing stocks in November. If you want to read about some more best performing stocks in November, go directly to 5 Best Performing Stocks in November. Afte...
13 december 2022
Johnson & Johnson (NYSE: JNJ) is in the midst of a transition. One way the business can accelerate its plans for growth is via acquisitions, and Johnson & Johnson has been busy on that front of late....
8 december 2022
DANVERS, Mass., December 05, 2022--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist.
5 december 2022
Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 december 2022
Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.
30 november 2022
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
22 november 2022
Volgende pagina